82.3% 12-month DOR for UroGen Pharma's UGN-102 in Phase 3 Envision trial for bladder cancer treatment.
UroGen Pharma announces 82.3% 12-month duration of response from Phase 3 Envision trial of UGN-102 for bladder cancer treatment. This trial demonstrated a 79.6% three-month complete response rate and 82.3% DOR at 12 months, reinforcing the drug's potential to be the first FDA-approved non-surgical option for LG-IR-NMIBC. UroGen's stock has risen 46.48% following the announcement.
June 13, 2024
5 Articles